Clinical Trial

A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1

Study acronym: FREEDOM2-DM1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to learn about the effects of an investigational medicine, PGN-EDODM1, to see how safe and tolerable multiple administrations of PGN-EDODM1 are for people with myotonic dystrophy type 1 (DM1) compared to placebo.
Protocol Amendment History 3 changes
notable Trial sites expanded: 8 -> 12 locations 2026-07-30
notable Primary completion pushed: 2026-08 -> 2027-03 2026-04-29
minor Completion pushed: 2026-08 -> 2027-03 2026-04-29
Trial Details
NCT Number NCT06667453
Lead Sponsor PepGen Inc
Conditions Myotonic Dystrophy 1
Enrollment 24 participants
Start Date 2024-12-10
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-29